| Project/Area Number |
17H06895
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
Takedachi Kyoko 広島大学, 原爆放射線医科学研究所, 研究員 (00806557)
|
|---|
| Project Period (FY) |
2017-08-25 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 白血病幹細胞 / Geminin / 未分化性維持 / 細胞周期 |
|---|
| Outline of Final Research Achievements |
In this study, we aimed for the search of the new therapy to target of leukemia stem cells. We think it is important to understand that elucidation of the cell cycle and epigenome control to the development of the therapy. Geminin protein regulates the cell cycle and epigenome. Therefore, we focused on the role of Geminin in the regulation of leukemia stem cell activity. And we found that Geminin was an effective target in the new therapeutic drugs which target in leukemia stem cells. Toward the development of the new therapy that targeted Geminin, we will aim at the construction of the theoretical base in future.
|
| Academic Significance and Societal Importance of the Research Achievements |
申請者のグループはこれまでの研究で、Gemininが造血幹細胞の活性を制御において中核因子として機能していることを世界に先駆けて明らかにしてきた。つまり白血病幹細胞の活性制御におけるGemininの役割を解明する本研究は世界でも類を見ない独創的な研究であるといえる。また本研究は、Gemininが白血病幹細胞を標的とした治療薬において新たな標的となることを導き出した。つまり本研究成果は、白血病幹細胞の根絶を目指した新規治療法の開発に貢献できたと考えられる。
|
